Endogenous depression

Summary

Endogenous depression (MONDO:0012048) is a disease and 1,945 clinical trials. Top therapeutic interventions include escitalopram, fluoxetine, and citalopram. A subtype of major depressive disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1,945

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endogenous depression
Mondo ID	MONDO:0012048
DOID	DOID:1595
NCIT	C34532
SNOMED CT	300706003
UMLS	C0011573
MedGen	3763
Is cancer (heuristic)	no

Also known as: major depressive disorder · MDD

Disease family

This is a subtype of major depressive disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › mood disorder › depressive disorder › major depressive disorder › endogenous depression

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1,945.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	269
PHASE2	264
PHASE4	217
Not specified	153
PHASE1	101
PHASE1/PHASE2	39
PHASE2/PHASE3	36
EARLY_PHASE1	21

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02129751	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
NCT02752542	PHASE4	RECRUITING	Personalized Indications for CBT and Antidepressants in Treating Depression
NCT05004987	PHASE4	RECRUITING	Aβ Dynamics in LLMD
NCT05017311	PHASE4	RECRUITING	Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
NCT05273996	PHASE4	ACTIVE_NOT_RECRUITING	Predictors of Cognitive Outcomes in Geriatric Depression
NCT05450432	PHASE4	RECRUITING	Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
NCT05892744	PHASE4	RECRUITING	Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
NCT05950711	PHASE4	ACTIVE_NOT_RECRUITING	Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
NCT06103760	PHASE4	RECRUITING	Positioning of Esketamine Treatment in the Real-world Management of Depression
NCT06213324	PHASE4	RECRUITING	Neural Circuit Effects of Ketamine in Depression
NCT06223880	PHASE4	RECRUITING	A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06417437	PHASE4	RECRUITING	Non-invasive BCI and Application Verification for Depressed People
NCT06426485	PHASE4	NOT_YET_RECRUITING	To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets
NCT06580041	PHASE4	ENROLLING_BY_INVITATION	Precision Care for Major Depressive Disorder
NCT06610305	PHASE4	RECRUITING	Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
NCT06644833	PHASE4	NOT_YET_RECRUITING	Effective of Transcranial Magnetic Stimulation (TMS) vs Treatment as Usual for First-Episode Depression in Adults
NCT06675851	PHASE4	RECRUITING	Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People
NCT06699966	PHASE4	NOT_YET_RECRUITING	Stony Brook Medicine Anti-Inflammatory Trial
NCT06749470	PHASE4	NOT_YET_RECRUITING	A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules
NCT07011693	PHASE4	NOT_YET_RECRUITING	Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)
NCT07076342	PHASE4	RECRUITING	The Role of mGluR5 in CBT-I
NCT07095205	PHASE4	RECRUITING	PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
NCT07105111	PHASE4	RECRUITING	A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07136714	PHASE4	RECRUITING	Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
NCT07139106	PHASE4	NOT_YET_RECRUITING	Understanding the Role of the Kappa Opioid Receptor in Ketamine’s Attenuation of Suicidal Thoughts
NCT07555743	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia
NCT00000375	PHASE4	COMPLETED	Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder
NCT00049972	PHASE4	COMPLETED	Major Depressive Disorder Study In Adults
NCT00157547	PHASE4	COMPLETED	Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression
NCT00166114	PHASE4	COMPLETED	Depression, Epinephrine, and Platelet Function
NCT00182533	PHASE4	TERMINATED	Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
NCT00186446	PHASE4	COMPLETED	Treatment of Nicotine Dependence and Acute Depression
NCT00188942	PHASE4	COMPLETED	A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder
NCT00191932	PHASE4	COMPLETED	Switching to Duloxetine From Other Antidepressants
NCT00208169	PHASE4	COMPLETED	Abilify Therapy for Reducing Comorbid Substance Abuse
NCT00223197	PHASE4	COMPLETED	Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse
NCT00234195	PHASE4	COMPLETED	Wellbutrin XL, Major Depressive Disorder and Breast Cancer
NCT00313417	PHASE4	TERMINATED	Creatine as a New Therapeutic Strategy in Depression
NCT00316160	PHASE4	COMPLETED	Sexual Functioning Study With Antidepressants
NCT00321152	PHASE4	COMPLETED	A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ESCITALOPRAM	4	105
FLUOXETINE	4	69
CITALOPRAM	4	53
BUPROPION	4	49
VENLAFAXINE	4	49
VILAZODONE	4	40
DULOXETINE	4	30
VORTIOXETINE	4	30
PAROXETINE	4	29
DESVENLAFAXINE	4	27
CARIPRAZINE	4	21
BREXPIPRAZOLE	4	19
SERTRALINE	4	17
KETAMINE	4	16
DEXTROMETHORPHAN	4	15
AGOMELATINE	4	11
APREPITANT	4	9
MIRTAZAPINE	4	9
ARIPIPRAZOLE	4	7
CYCLOSERINE	4	6
LEVOMILNACIPRAN	4	5
LUMATEPERONE	4	5
NITROUS OXIDE	4	5
ZURANOLONE	4	5
FLUVOXAMINE MALEATE	4	4
MIFEPRISTONE	4	4
QUETIAPINE FUMARATE	4	4
TRAZODONE	4	4
AMISULPRIDE	4	3
ESKETAMINE	4	3